ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Michael E. Burt
Amir Abolhoda
Robert J. Ginsberg
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burt, M. E.
Right arrow Articles by Brennan, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burt, M. E.
Right arrow Articles by Brennan, M. F.

Ann Thorac Surg 2000;69:1542-1549
© 2000 The Society of Thoracic Surgeons

Original articles: General thoracic

Isolated lung perfusion for patients with unresectable metastases from sarcoma: a phase I trial

Michael E. Burt, MD, PhDa, David Liu, MDa, Amir Abolhoda, MDa, Howard M. Ross, MDa, Yoshikazu Kaneda, MDa, Ellen Jara, BAa, Ephraim S. Casper, MDa, Robert J. Ginsberg, MDa, Murray F. Brennan, MDa

a Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Address reprint requests to Dr Brennan, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021
e-mail: brennanm{at}mskcc.org

Background. In patients with unresectable pulmonary metastases from sarcoma, systemic chemotherapy has had limited efficacy possibly because of dose-limiting toxicities. Isolated lung perfusion is an alternative method of delivering high-dose chemotherapy to the lungs while minimizing systemic toxicities. We present the results of our Phase I trial of isolated lung perfusion with doxorubicin hydrochloride in such a group of patients.

Methods. From May 1995 to June 1997, 8 patients with unresectable metastases from sarcoma limited to the lungs underwent isolated lung perfusion with doxorubicin. A dose-escalation schedule starting at 40 mg/m2 was used. Seven patients were treated with a dose of 40 mg/m2 or less, and 1 patient received 80 mg/m2. Blood, tumor, and normal lung samples were obtained at various time points during the operation. Patients were evaluated for cardiac, pulmonary, and other toxicities.

Results. The doxorubicin concentrations in both normal lung and tumor correlated directly with the amount of doxorubicin in the perfusate. The tumors took up less doxorubicin than the lung. All patients had minimal or undetectable systemic levels of doxorubicin at the conclusion of the perfusion. There were no cardiac or other systemic toxicities. In the 7 patients perfused with 40 mg/m2 or less of doxorubicin, there was a significant decrease in the forced expiratory volume in 1 second and a trend toward a significant decrease in diffusing capacity. The patient who received 80 mg/m2 underwent lung scanning postoperatively, and scans showed no ventilation or perfusion in the perfused lung. There were no perioperative deaths. Two patients are alive with disease, and 6 patients died of disease. The median follow-up is 11 months and the longest, 31 months. There were no partial or complete responses. One patient had stabilization of disease in the perfused lung, whereas the lesions in the untreated lung progressed markedly.

Conclusion. Isolated lung perfusion is well tolerated by patients and effectively delivers high doses of doxorubicin to the lung and tumor tissues while minimizing systemic toxicities. A single dose of 80 mg/m2 resulted in substantial injury to the lung. There were no partial or complete responses in patients perfused with doxorubicin at the maximum tolerated dose of 40 mg/m2. Isolated lung perfusion remains a model for testing new and innovative therapies for metastatic sarcoma.




This article has been cited by other articles:


Home page
 ICVTSHome page
C. Cheng, A. Haouala, T. Krueger, F. Mithieux, J. Y. Perentes, S. Peters, L. A. Decosterd, and H.-B. Ris
Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin
Interactive CardioVascular and Thoracic Surgery, June 1, 2009; 8(6): 635 - 638.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
H. Yan, C. Cheng, A. Haouala, T. Krueger, J.-P. Ballini, S. Peters, L. A. Decosterd, I. Letovanec, H.-B. Ris, and S. Andrejevic-Blant
Distribution of Free and Liposomal Doxorubicin After Isolated Lung Perfusion in a Sarcoma Model
Ann. Thorac. Surg., April 1, 2008; 85(4): 1225 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. P. van Putte, M. Grootenboers, W.-J. van Boven, J. M. H. Hendriks, P. E. Y. van Schil, G. Guetens, G. De Boeck, G. Pasterkamp, F. Schramel, and G. Folkerts
Pharmacokinetics of Gemcitabine when Delivered by Selective Pulmonary Artery Perfusion for the Treatment of Lung Cancer
Drug Metab. Dispos., April 1, 2008; 36(4): 676 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
P. E. Van Schil, J. M. Hendriks, B. P. van Putte, B. A. Stockman, P. R. Lauwers, P. W. ten Broecke, M. J. Grootenboers, and F. M. Schramel
Isolated lung perfusion and related techniques for the treatment of pulmonary metastases
Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 487 - 496.
[Abstract] [Full Text] [PDF]

Home page
 ICVTSHome page
C. Biancosino, M. Albert, and A. Linder
Acute toxicity of irinotecan in the ex-vivo isolated perfused human lung model high-dose therapy during isolated perfusion without acute toxic lung edema
Interactive CardioVascular and Thoracic Surgery, October 1, 2007; 6(5): 583 - 587.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. Krueger, A. Kuemmerle, S. Andrejevic-Blant, H. Yan, Y. Pan, J.-P. Ballini, W. Klepetko, L. A. Decosterd, R. Stupp, and H.-B. Ris
Antegrade Versus Retrograde Isolated Lung Perfusion: Doxorubicin Uptake and Distribution in a Sarcoma Model
Ann. Thorac. Surg., December 1, 2006; 82(6): 2024 - 2030.
[Abstract] [Full Text] [PDF]

Home page
 PerfusionHome page
M. J. Grootenboers, J. Heeren, B. P Van putte, J. M. Hendriks, W. J Van boven, P. E. Van schil, and F. M. Schramel
Isolated lung perfusion for pulmonary metastases, a review and work in progress
Perfusion, September 1, 2006; 21(5): 267 - 276.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. P. van Putte, J. M.H. Hendriks, G. Guetens, G. de Boeck, E. A. de Bruijn, P. E.Y. van Schil, and G. Folkerts
Modified approach of administering cytostatics to the lung: more efficient isolated lung perfusion.
Ann. Thorac. Surg., September 1, 2006; 82(3): 1033 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
T. Krueger, A. Kuemmerle, M. Kosinski, A. Denys, L. Magnusson, R. Stupp, A. B. Delaloye, W. Klepetko, L. Decosterd, H.-B. Ris, et al.
Cytostatic lung perfusion results in heterogeneous spatial regional blood flow and drug distribution: Evaluation of different cytostatic lung perfusion techniques in a porcine model.
J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 304 - 311.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
B. P. v. Putte, A. Huisman, J. M.H. Hendriks, P. E.Y. v. Schil, W. J. v. Boven, F. Schramel, F. Nijkamp, and G. Folkerts
Pulmonary intravascular volume can be used for dose calculation in isolated lung perfusion
Eur. J. Cardiothorac. Surg., October 1, 2005; 28(4): 594 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
M. Jinbo, K. Ueda, Y. Kaneda, M. Sudo, T.-S. Li, and K. Hamano
Video-assisted transcatheter lung perfusion regional chemotherapy
Eur. J. Cardiothorac. Surg., June 1, 2005; 27(6): 1079 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. J. Vogl, A. Wetter, S. Lindemayr, and S. Zangos
Treatment of Unresectable Lung Metastases with Transpulmonary Chemoembolization: Preliminary Experience
Radiology, March 1, 2005; 234(3): 917 - 922.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J. M. H. Hendriks, M. J. J. H. Grootenboers, F. M. N. H. Schramel, W. J. van Boven, B. Stockman, H. T. M. ter Beek, C. A. Seldenrijk, P. ten Broecke, C. A. J. Knibbe, P. Slee, et al.
Isolated Lung Perfusion With Melphalan for Resectable Lung Metastases: A Phase I Clinical Trial
Ann. Thorac. Surg., December 1, 2004; 78(6): 1919 - 1927.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
U. F.W. Franke, T. Wittwer, M. Lessel, K. Liebing, M. Albert, V. Becker, H. Schubert, and T. Wahlers
Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: I. Influence of perfusion pressure and hyperthermia on functional and morphological lung integrity
Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
U. F.W. Franke, T. Wittwer, M. Kaluza, M. Albert, V. Becker, M. Roskos, M. Lessel, and T. Wahlers
Evaluation of isolated lung perfusion as neoadjuvant therapy of lung metastases using a novel in vivo pig model: II. High-dose cisplatin is well tolerated by the native lung tissue
Eur. J. Cardiothorac. Surg., October 1, 2004; 26(4): 800 - 806.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. P. Van Putte, J. M. H. Hendriks, S. Romijn, B. Pauwels, G. De Boeck, G. Guetens, E. De Bruijn, and P. E. Y. Van Schil
Pharmacokinetics after pulmonary artery perfusion with gemcitabine
Ann. Thorac. Surg., October 1, 2003; 76(4): 1036 - 1040.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. P. Van Putte, J. M.H. Hendriks, S. Romijn, G. Guetens, G. De Boeck, E. A. De Bruijn, and P. E.Y. Van Schil
Single-pass isolated lung perfusion versus recirculating isolated lung perfusion with melphalan in a rat model
Ann. Thorac. Surg., September 1, 2002; 74(3): 893 - 898.
[Abstract] [Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
C. Schroder, S. Fisher, A. C. Pieck, A. Muller, U. Jaehde, H. Kirchner, A. Haverich, and P. Macchiarini
Technique and results of hyperthermic (41{degrees}C) isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis
Eur. J. Cardiothorac. Surg., July 1, 2002; 22(1): 41 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Schneider, S. Kampfer, C. Loddenkemper, T. Foitzik, and H. J. Buhr
Chemoembolization of the Lung Improves Tumor Control in a Rat Model
Clin. Cancer Res., July 1, 2002; 8(7): 2463 - 2468.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. S. Schrump, S. Zhai, D. M. Nguyen, T. S. Weiser, B. A. Fisher, R. E. Terrill, B. M. Flynn, P. H. Duray, and W. D. Figg
Pharmacokinetics of paclitaxel administered by hyperthermic retrograde isolated lung perfusion techniques
J. Thorac. Cardiovasc. Surg., April 1, 2002; 123(4): 686 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. Tanaka, Y. Kaneda, T.-S. Li, T. Matsuoka, N. Zempo, and K. Esato
Digitonin enhances the antitumor effect of cisplatin during isolated lung perfusion
Ann. Thorac. Surg., October 1, 2001; 72(4): 1173 - 1178.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2000 by The Society of Thoracic Surgeons.